جست‌وجوی استاد و پژوهشگر

Stephen E. Braunمشاهده پروفایل

استادیار

• Gene Therapy
• HIV/AIDS Research
• Virology
• +۵ مورد دیگر

Stephen E. Braun is an Assistant Professor of Pharmacology at Tulane University. His research focuses on gene therapy strategies targeting lympho-hematopoietic cells, with a strong emphasis on HIV/AIDS research. He has over 25 years of experience in translational research, including studies in non-human primates (NHP) and clinical trial advancements. His work involves developing CAR T-cell therapies, lentiviral vector engineering, and mesenchymal stem cell-based antiviral approaches. Education: BS in Genetics and Cell Biology, Biochemistry, University of Minnesota (1987) PhD in Genetics, University of Minnesota (1993) Postdoctoral Fellowship at Walther Oncology Center, Indiana University School of Medicine (1993–1997) Research Interests: Dr. Braun’s lab develops novel gene therapy approaches to combat HIV/AIDS, including CAR T-cell redirection, HIV-resistant T-cell engineering, and MSC-mediated viral inhibition. His work bridges in vitro studies with large-animal models and clinical application. Key Awards: NIH Post-Doctoral Training Award (1993–1995) Leukemia Society of America Fellow Award (1995–1998) Center for AIDS Research Scholar Award (2003–2006) Early Investigator Award (30th Annual NHP AIDS Symposium, 2012) Grants & Collaborations: His research has been supported by NIH and private foundations. Collaborations span institutions such as the National Primate Research Centers and the American Society of Gene & Cell Therapy. Labs/Teams: Active in Tulane’s Division of Veterinary Medicine and collaborates with the Comparative Pathology and Immunology research groups.

• Gene Editing
• Hematology
• Immunology
• +۳ مورد دیگر

Pietro Genovese is an Assistant Professor of Pediatrics at Boston Children's Hospital, specializing in gene editing and hematopoietic stem cell research. His work focuses on developing therapeutic strategies for genetic disorders, immunodeficiencies, and cancer through advancements in CRISPR/Cas9 and base editing technologies. Genovese leads the Genovese Lab, investigating topics such as hematopoietic stem cell function preservation, clonal tracking, and targeted immunotherapies for acute myeloid leukemia and SCID-X1. Research Interests: Gene Editing in Stem Cells, Hematological Disorders, Immune Engineering, Oncology, and Genetic Disease Correction. His lab's innovations include enhancing gene editing efficiency while minimizing DNA damage responses, as well as optimizing viral vector production for therapeutic applications. Genovese collaborates extensively with institutions like Harvard Medical School and co-authors frequently on topics like CAR-T cell reprogramming and mesenchymal stromal cell support in transplants. Publications highlight breakthroughs in areas such as CX3CR1 haploinsufficiency effects in transplant recipients, IL-12-modified NK T cells for tumor targeting, and epitope editing for leukemia treatment. His work bridges basic science with clinical translation, aiming to cure genetic blood disorders and advance cellular therapies. Labs/Teams: Genovese Lab (active on Twitter @Genovese_Lab). Collaborations include global teams in gene therapy development and stem cell biology.

Fabio Candottiمشاهده پروفایل

استاد

• Immunodeficiency
• Gene Therapy
• Pediatrics
• +۷ مورد دیگر

Fabio Candotti is a full professor at the University of Lausanne (UNIL) in the Faculty of Biology and Medicine and serves as head physician in the Department of Immunology and Allergology at the Lausanne University Hospital (CHUV). A world-renowned expert in immunodeficiency, pediatrics, and gene therapy, he has held academic and research leadership roles in both the United States and Europe, including a long tenure at the National Institutes of Health (NIH). Born: 1962, Italian nationality Education: MD, University of Brescia (1987); specialization in pediatrics (University of Pavia) and immunology/allergology (Brescia) Postdoctoral training: National Institutes of Health (NIH), USA (1992) Academic appointments: Associate Professor at UNIL (2014), promoted to Full Professor (2022) Prior roles: Senior Investigator and Head of Immune Diseases Section, NHGRI/NIH; Head, NIH Gene Therapy Interest Group His research and clinical work focus on primary immunodeficiencies, particularly adenosine deaminase deficiency (ADA) and Wiskott-Aldrich syndrome (WAS). He investigates the molecular and cellular mechanisms underlying immune dysregulation, autoimmunity, and metabolic defects in these disorders. His work has revealed how high adenosine levels and DNA repair deficiencies contribute to inflammatory, fibrogenic, and oncogenic processes in ADA-deficient patients. Using murine models, he has advanced understanding of autoimmune complications in WAS. A major focus of his work is the development and application of gene therapy strategies, including viral vector-based tools and transgenesis, for curative treatments. The trends in his recent publications highlight sustained leadership in translational immunology and gene therapy, with recurring themes in immune reconstitution, metabolic consequences of immunodeficiency, long-term patient outcomes, and innovative therapeutic design. His work bridges basic science and clinical application, emphasizing durable correction of immune function and quality of life. He has received multiple scientific awards, including: National Institutes of Health Award of Merit (1999, 2006) National Human Genome Research Institute Service Award (2002) US Government Service Award (2003, 2008) Best Docs in Northern Virginia (2009) Candotti is actively involved in medical education, having taught at Metropolitan Washington D.C. Medical Genetics since 2004 and contributed to numerous fellowship and residency training programs in immunology and hematology. He is an adjunct member of the Graduate Faculty at the University of Medicine and Dentistry of New Jersey. He also contributes to the scientific community through editorial roles in journals such as Clinical and Translational Science , The Open Gene Therapy Journal , Frontiers in Primary Immunodeficiencies , and Journal of Clinical Immunology . He is a member of the Italian Society of Pediatric Allergology and Immunology, the American Society for Gene Therapy, and the European Society for Immunodeficiencies. His work is supported by long-term patient cohorts and clinical studies aimed at developing new drugs and gene-based therapies. He leads a research team focused on advancing gene therapy for monogenic immune disorders, with a vision of translating laboratory discoveries into safe and effective clinical applications.

Hind J. Fadelمشاهده پروفایل

استادیار

• Virology
• Gene Therapy
• HIV Cure Research
• +۱۲ مورد دیگر

Hind J. Fadel, M.D., Ph.D., is an Assistant Professor of Medicine at Mayo Clinic in Rochester, Minnesota, with a primary appointment as Consultant in the Division of Infectious Diseases, Department of Internal Medicine, and a joint appointment in the Department of Molecular Medicine. Her work bridges clinical practice and translational research in virology and gene therapy. Education: Ph.D. in Virology and Gene Therapy, Mayo Graduate School, Mayo Clinic College of Medicine Residency in Infectious Disease, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine Residency in Internal Medicine, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine M.D., Saint Joseph University, Faculty of Medicine Dr. Fadel’s research focuses on the molecular biology of viral replication, particularly HIV, and the development of genome engineering tools such as CRISPR-Cas and TALENs to create HIV-resistant immune cells and advance cure strategies. Her lab also investigates host-pathogen interactions in emerging viruses like Ebola, influenza, and chikungunya. She employs humanized mouse models and advanced molecular techniques to study viral integration and host factors such as LEDGF/p75. Her work has significant implications for regenerative medicine and cell-mediated immunotherapeutics. The most recent publications reflect a strong trajectory in HIV molecular virology, antiviral mechanisms, and host-pathogen dynamics, with extensions into public health research during the COVID-19 pandemic and co-infection outcomes. Her studies often involve multi-center collaborations and utilize structural, biochemical, and clinical data. Scientific Awards: Young Investigator Award, 21st Conference on Retroviruses and Opportunistic Infections (2014) Young Investigator Award, 19th Conference on Retroviruses and Opportunistic Infections (2012) Division of Infectious Diseases Research Fellows' Award, Mayo Clinic (2011) Award-winning poster, North Central Chapter of IDSA (2010) Dr. Fadel is actively involved in mentoring residents, graduate students, and fellows, and contributes to education in infectious diseases. She is a member of the Infectious Diseases Society of America, Minnesota Medical Association, and the Institutional Biosafety Committee at Mayo Clinic. Her clinical expertise includes ICU infections, care of immunocompromised patients, and outpatient management of HIV/AIDS. Her research is conducted within the interdisciplinary environment of Mayo Clinic, utilizing core facilities in molecular medicine and infectious disease research. She collaborates across departments and institutions, contributing to both basic science and clinical trials infrastructure.

• Gene Therapy
• Hematopoietic Stem Cell Engineering
• CRISPR Gene Editing
• +۵ مورد دیگر

Jennifer Eileen Adair, PhD is a Professor in the Department of Genetic and Cellular Medicine at UMass Chan Medical School, with dual appointments in the T.H. Chan School of Medicine. Her research bridges basic science with translational applications in gene and cell therapy. Dr. Adair earned her BS in Chemistry from Youngstown State University and her PhD in Genetics and Cell Biology from Washington State University. Her academic journey has focused on developing innovative approaches to gene therapy with an increasing emphasis on global accessibility. Her research program centers on gene therapy development , particularly in hematopoietic stem cell engineering , CRISPR-based gene editing , and manufacturing optimization for cell and gene therapies. Recent work demonstrates a strong commitment to addressing global health disparities, with multiple publications on making gene therapies accessible in low- and middle-income countries through localized manufacturing solutions. Her laboratory investigates fundamental questions about stem cell biology while developing practical applications for genetic disorders including Fanconi anemia. Analysis of her recent publications (2020-2024) shows a strategic shift toward addressing implementation challenges of gene therapies, with approximately 40% of her work now focused on manufacturing, accessibility, and global health equity issues. Her research combines molecular biology, stem cell engineering, and health systems analysis to create practical solutions for bringing advanced therapies to diverse patient populations worldwide. Dr. Adair has established herself as a leader in both the technical development of gene therapies and the critical discourse around their global implementation. Her work spans from basic molecular mechanisms to health policy considerations, reflecting a comprehensive approach to advancing the field. She actively collaborates with international teams to address the translational gap in gene therapy, with recent projects spanning multiple continents and involving partnerships with researchers in India, Africa, and South America. Her laboratory focuses on developing point-of-care manufacturing solutions that could democratize access to these life-saving treatments.

• Reproductive medicine
• Reproduction
• Sociology of family and relationships
• +۳ مورد دیگر

Suzy Buckley is an Associate Professor in Reproductive Health at University College London , where she has been affiliated since joining in 2006. She served as a Lecturer from 2013 and was promoted to Associate Professor in 2021. Additionally, she held the role of Vice Dean for Equality, Diversity and Inclusion in the Faculty of Population Health Sciences from 2018 to 2023. PhD in Gene Therapy from Imperial College London (2003) MSc in Biochemistry from University of Oxford (1998) Her research bridges Reproductive Medicine and Sociology of Family Relationships , focusing on the impact of societal inequalities on alternative families in assisted reproduction. She collaborates with the Human Fertilisation and Embryology Authority (HFEA) and Donor Conception Network (DCN) to study solo mothers and donor-conceived parenting. Prior to this, she conducted groundbreaking gene therapy research for fetal and neonatal disorders using adeno-associated virus vectors and bioluminescent imaging . Scientific Awards : Instrumental in securing Gold Athena SWAN Award for UCL's Institute for Women's Health (2017) Contributed to Gold Athena SWAN renewal (2020) As Co-Director of Education at the Institute for Women's Health, she oversees four MSc, one MRes, and one iBSc program. Her EDI advocacy and reproductive health research align with UN Sustainable Development Goal 3 (Good Health and Wellbeing) .

• Biotechnology
• Cell Culture Technology
• Molecular Biotechnology
• +۳ مورد دیگر

Thomas Noll is a full Professor at Bielefeld University , affiliated with the Faculty of Engineering and leading the Cell Culture Technology Working Group . He serves as a Member of the Faculty Conference (University Professors) , Member of the Habilitation Committee , and Chair of the Molecular Biotechnology (Master) Examination Board . His work bridges biotechnology with engineering principles and interdisciplinary applications. His research focuses on CHO cell cultivation , perfusion processes , bioprocessing optimization , and biotechnological solutions for climate change . He integrates CRISPR/Cas9 for site-specific genetic integration and investigates hyperosmolality stress responses in cell cultures. The recent Google Scholar articles highlight a sustained research trajectory in lentivirus production , CHO secretome analysis , and sustainable biotechnologies . These works emphasize process intensification, proteome dynamics, and interdisciplinary approaches to biopharma and environmental challenges. Professor Noll contributes to academic governance as a board member of the Center for Biotechnology (CeBiTec) and through Molecular Biotechnology module responsibilities . His leadership spans interdisciplinary biotechnology , cell culture engineering , and industrial biotech education . No explicit teaching or lab details are provided in the scraped text.

• Pulmonology
• Critical Care Medicine
• Pulmonary Hypertension
• +۲ مورد دیگر

Renli Qiao is Clinical Associate Professor of Medicine at Keck School of Medicine, University of Southern California. As an attending physician, he practices pulmonary medicine and critical care at Keck Hospital's Pulmonary Clinic and ICU, specializing in lung transplantation services. His research focuses on pulmonary hypertension, mechanical ventilation, and critical care management. Qiao maintains international collaborations, frequently lecturing at Peking Union Medical College in China. His publications address COVID-19 management, critical care quantification, and pulmonary medicine development in China. Research funding includes grants from the American Lung Association. Clinical expertise encompasses complex case management in pulmonary and critical care medicine.

Chantelle Ahlenstielمشاهده پروفایل

پژوهشگر ارشد

• Virology
• Infectious Diseases
• Gene Therapy
• +۳ مورد دیگر

Dr. Chantelle Ahlenstiel is a Senior Research Fellow at the Kirby Institute, University of New South Wales, in the Immunovirology & Pathogenesis Program. She holds a Bachelor of Advanced Science (Hons 1st class) from the University of Sydney (2000) and a PhD in Infectious Diseases from the same university (2004). She was awarded an NIH Visiting Fellowship for postdoctoral training at the Vaccine Research Center, NIH (2004-2009). Her research focuses on RNA-directed epigenetic silencing of HIV-1 and SIV, with projects including live cell imaging of siRNA trafficking, the role of F-actin in transcriptional gene silencing, and in vivo studies using humanized mouse models. She also investigates nanoparticle delivery of si/shRNA for HIV-1 therapy. Dr. Ahlenstiel has received the NIH Visiting Fellowship award. She supervises one Master's and two PhD students. She is the recipient of the NHMRC Project Grant APP1128012. She leads research in the Immunovirology & Pathogenesis Program at the Kirby Institute.

• Gene therapy
• Cell therapy
• Hematopoietic stem cells
• +۶ مورد دیگر

Luigi Naldini is a renowned Italian scientist and academic at San Raffaele Vita-Salute University , serving as Director of the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) since 2008. Over a 25-year career, he has revolutionized gene therapy through lentiviral vector development, impacting genetic disease treatment, cancer immunotherapy, and stem cell research.

Sam Kungمشاهده پروفایل

استاد

• Immunology
• Cancer Immunology
• Gene Therapy
• +۳ مورد دیگر

Sam Kung is a Professor in the Department of Immunology at the Max Rady College of Medicine, University of Manitoba. He holds the position of Director of the Lentiviral Vector Viral Particles Production Core Platform. His research focuses on natural killer (NK) cell biology, including their migration dynamics, interactions with dendritic cells, and roles in tumor microenvironments. His work integrates gene therapy platforms and microfluidics to advance immunotherapy strategies for cancer. Dr. Kung earned his B.Sc. and MPhil from the University of Hong Kong, followed by a PhD in immunology from the University of Toronto. He completed postdoctoral training at UCLA in lentiviruses and gene therapy. His research has been supported by grants such as the CFI-funded lab and Manitoba Medical Service Foundation awards. Award highlights include multiple Excellence in Teaching Awards from the Immunology Department and a Terry Fox Postdoctoral Fellowship. He is actively involved in professional organizations like the Canadian Society of Immunology and the Society for Natural Immunity. Current affiliations include the CancerCare Breast Cancer Research Group, Prairie Infectious Immunology Network, and Manitoba Epigenetics Network. His lab’s innovations include protocols for genetic engineering of primary NK cells and live-cell analysis platforms for immune cell interactions.

• Immunology
• T cell biology
• Autoimmune diseases
• +۵ مورد دیگر

Professor Hans-Willi Mittrücker is a distinguished immunologist at the Institute for Immunology within the University Hospital Hamburg-Eppendorf (UKE). With over 150 publications to his name, his research focuses on fundamental mechanisms of T cell biology and their implications in autoimmune and infectious diseases. His work spans multiple research areas including kidney inflammation, liver immunology, and pregnancy-related immune responses. His primary research interests include: T cell differentiation and effector functions Interferon regulatory factors in immune responses Purinergic signaling in immune regulation Autoimmune glomerulonephritis Maternal-fetal immune interactions Intestinal immunity and mucosal homeostasis Professor Mittrücker's recent publications demonstrate a strong focus on the molecular mechanisms of T cell memory, cytokine regulation, and the role of specific signaling pathways in autoimmune conditions. His work on interferon regulatory factors, purinergic receptors, and T cell subsets in organ-specific inflammation has provided significant insights into disease pathogenesis and potential therapeutic targets. The research shows a consistent trajectory toward understanding how T cell responses can be modulated in various disease contexts, with implications for developing targeted immunotherapies. Professor Mittrücker has secured substantial research funding through multiple German Research Foundation (DFG) projects, including: SFB 1328 A03: Regulation of T cell differentiation and effector functions by adenine nucleotides (2018-2022) MI 476/5-2: Influenza during pregnancy and consequences for mother and child (2018-2023) SFB 1192 A04: Autoreactive T cell responses in glomerulonephritis (2016-2019) MI 476/7-1: Role of Interferon Regulatory Factor 4 in T cell memory (2017-2021) His laboratory investigates T cell responses using sophisticated mouse models of infection and autoimmunity, with particular expertise in analyzing small T cell populations and their functional properties. Current research directions include understanding how pregnancy alters antiviral immunity, mechanisms of tissue-resident memory T cells, and the role of specific ion channels and signaling molecules in T cell function.

• Immunology
• Medical Microbiology
• Paediatrics and Reproductive Medicine
• +۳ مورد دیگر

Cecilia Johansson is a Professor of Mucosal Immunology at the National Heart & Lung Institute, part of the Faculty of Medicine at Imperial College London. Her academic journey includes undergraduate studies at Umeå and Lund Universities (Sweden), a PhD in Immunology from Lund University, and postdoctoral training at the NIH, USA. She leads a research group investigating immunity during viral infections, particularly focusing on type I interferons' role in lung inflammation and cancer interactions. Her affiliations include the Asthma UK Centre for Asthma and Allergy, the Immuno-Pathology Network, and the Imperial Network for Vaccine Research. She organizes the Imperial CREST Academy, fostering science education for students aged 16-18. Her work is supported by grants from MRC, BBSRC, Wellcome Trust, and others. Research interests span mucosal immunology, viral pathogenesis, T cell responses, and innate immunity. Her lab explores how viral infections influence lung cancer progression and develops vaccine strategies using lentiviral and AAV vectors. Recent studies highlight the interplay between neutrophils, cytokines, and viral outcomes in RSV and SARS-CoV-2 models.

Stuart Ellisonمشاهده پروفایل

پژوهشگر

• Gene Therapy
• Stem Cell Biology
• Neurodegenerative Diseases
• +۳ مورد دیگر

Dr. Stuart Ellison is an academic researcher affiliated with the University of Manchester, contributing to the UN Sustainable Development Goals through his work in medical research. He leads projects in the Stem Cell and Neurotherapies group, focusing on gene and stem cell therapies for disorders like Mucopolysaccharidosis and neurodegenerative diseases. His expertise spans preclinical studies, lentiviral vector development, and GMP-compliant cell manufacturing. Education: Bachelor of Science in Biochemistry with Molecular Biology (2004), UMIST PhD in Cardiovascular Sciences (2010), University of Birmingham Research Interests: His work bridges biochemistry and clinical applications, emphasizing: - Gene therapy for neuromuscular and neurological disorders - Stem cell-based treatment strategies for lysosomal storage diseases - Development of novel viral vectors for targeted drug delivery Publications Trends: Recent articles highlight advancements in MPS therapies, neurodegeneration mechanisms, and immune system interactions in lysosomal diseases. Collaborations focus on translating preclinical findings into clinical applications. Labs/Teams: Active within the Stem Cell and Neurotherapies group at the University of Manchester, contributing to interdisciplinary research in regenerative medicine and genetic therapies.

Bernardo Maria Esterمشاهده پروفایل

دانشیار

• Gene Therapy
• Hematopoietic Stem Cell Transplantation
• Pediatric Immunohematology
• +۵ مورد دیگر

Bernardo Maria Ester serves as Associate Professor of Pediatrics at Vita-Salute San Raffaele University's School of Medicine, where he holds multiple leadership roles including Member of the Steering Committee for the PhD Program in Molecular Medicine and Deputy Director of its 'Cell and Gene Therapy' curriculum. His clinical work centers at IRCCS San Raffaele Hospital as Head of the Pediatric Immuno-hematology Unit and Coordinator of the Pediatric Allogeneic Transplant Area. PhD in Biological Characterization and Clinical Application of Human Mesenchymal Stem Cells (Leiden University, 2010) Specialization in Pediatrics (University of Pavia, 2005, cum laude ) Degree in Medicine and Surgery (University of Pavia, 2000, cum laude ) His research bridges clinical practice and laboratory investigation with focus on gene therapy for metabolic disorders and hematopoietic stem cell transplantation . As a translational physician-scientist, he pioneered the first-in-human lentiviral gene therapy trial for Mucopolysaccharidosis Type I (Hurler variant) serving as Principal Investigator. His work spans stem cell biology, immunomodulation using mesenchymal stromal cells, and therapeutic development for rare pediatric diseases including ADA-SCID and Metachromatic Leukodystrophy. Analysis of his 15 most recent publications reveals consistent focus on ex-vivo gene therapy (72% of works), with particular emphasis on mucopolysaccharidoses and lysosomal storage disorders. His clinical research examines long-term outcomes, skeletal manifestations, and real-world implementation challenges, while basic science contributions explore transgene optimization and immunomodulatory mechanisms. AIRC Investigator Grant (2009) for tumor angiogenesis research Ministry of Health Young Researcher Grant (2008) Telethon Foundation Core Grant as Principal Investigator (2016-2021) European Commission Framework Program participation (Allostem, RETHRIM) As an educator, he supervises PhD candidates across multiple institutions and mentors 4 pediatric residents annually. His clinical trials portfolio includes national and international studies on gene therapy for ADA-SCID, Wiskott-Aldrich syndrome, and beta-thalassemia. At SR-TIGET (San Raffaele Telethon Institute for Gene Therapy), he leads the Pediatric Clinical Research Unit and serves as Project Leader developing novel cellular therapies.